A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | MicrobiomeTrials
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2023-08-10Est. Completion: 2027-07-31
Enrollment target: 120 participants
Locations
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Calvary Mater Newcastle, Waratah, New South Wales, Australia
Royal Adelaide Hospital;Haematology Clinical Trials Unit, Adelaide, South Australia, Australia
St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia
The Alfred Hospital, Prahan, Victoria, Australia
The Chaim Sheba Medical Center - PPDS, Ramat Gan, Central District, Israel
Rambam Health Care Campus, Haifa, Israel
Hadassah University Hospital - Ein Kerem, Jerusalem, Israel
Tel Aviv Sourasky Medical Center PPDS, Tel Aviv, Israel
The Catholic University of Korea - Seoul St. Mary's Hospital (Kangnam St. Mary's Hospital), Seocho, South Korea
Seoul National University Hospital, Seoul, South Korea
Severance Hospital, Yonsei University Health System, Seoul, South Korea
Asan Medical Center., Seoul, South Korea
Samsung Medical Center - PPDS, Seoul, South Korea
Other microbiome trials you might be interested in